GlobeImmune Inc (GBIM) Fair Value & Analysis

Healthcare · US · Market cap $575

Below-average quality, currently priced close to our fair value.

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.

How to read this chart

60‑month range $0.0001 – $1.80 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

GlobeImmune Inc (GBIM) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Over the trailing twelve months, GlobeImmune Inc generated revenue of $6.2M at a net margin of -33.3%. Revenue declined 20.6% year over year. It earns a return on equity of -66.2%. The balance sheet holds a net cash position of $9.9M. Fundamentals as of Aug 17, 2026

The share trades about 80% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at 0%, GBIM screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms.

Full company description

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of NantCell, Inc.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2011 – FY2015 · reported fiscal years

GlobeImmune Inc reported revenue of $6.5M in FY2015 versus $5.1M in FY2011, a compound +6.0%/yr. Reported net income was −$2.8M in FY2015.

Watch GBIM: get an alert when its fair value changes →

Peer Group

Biotechnology · 599 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.